ASH 2024 preview – best of the rest
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Truqap could fill a prostate cancer gap
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
Merck & Co gets in on the bispecific act
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
